- The company has a number of products in various states of regulatory approval, each of which have a substantial market opportunity.
- Commercialization of three of its bigger solutions is imminent and the company is in talks with various partners to speed up the development and commercialization of some of its solutions.
- The suspension of non-essential medical procedures and clinical trials have caused some delays, but things seem to be improving already.
- The shares remain attractive for the risk tolerant investor.
PAVMed Is About To Enter The Commercialization Phase
June 13th, 2020 · No Comments